A new hope for treating prostate cancer complications has been approved for use in New Zealand.
Zometa treats the debilitating skeletal problems that are a major concern for men with advanced prostate cancer, and can be life threatening.
Between 65 and 75% of men with advanced prostate cancer suffer bone metastases. Without treatment, it can lead to gradual disintegration of the skeleton.
US studies found Zometa was the first drug that has been effective in treating bone metastases. The data showed that 25% fewer patients taking Zometa experienced any skeletal-related event compared to those taking the placebo.
